22
Dec
2020
Creative New Treatments for Mental Health: Steve Paul on The Long Run
Today’s guest on The Long Run is Steve Paul. Steve is the chairman, president and CEO of Boston-based Karuna Therapeutics. Karuna is developing new treatments for neuropsychiatric disorders. By the time you listen to this conversation, Karuna will either be very close to starting a Phase III clinical trial of its lead drug candidate, or it will already have begun.... Read More
21
Dec
2020
Celsius, Servier Forge Single-Cell Analysis Partnership in Colorectal Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Dec
2020
A Triumph of the Scientific Enterprise – Industry, Academia, and Government
Vaccines for COVID-19 are here. Some are looking for a fly in the ointment. But there’s no mistaking these vaccines protect 95 percent of people from getting sick from a virus that has killed 1.6 million people worldwide this year and threatens millions more. The one-two punch of messenger RNA vaccines for COVID-19 from Pfizer / BioNTech and Moderna in... Read More
16
Dec
2020
Startup Profiles: Exosite Drug Discovery & Efficient Gene Therapy for the Eye
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Dec
2020
Seeking Impact: Servier’s David Lee on The Long Run Podcast
Today’s guest on The Long Run is David Lee. David is the CEO of Boston-based Servier Pharmaceuticals. It’s the US subsidiary of France-based Servier Group. Servier, for those unfamiliar, is a rare bird in the pharmaceutical world. It markets both branded drugs and generic drugs. It is a truly global company with 21,000 employees in 148 countries, but it has... Read More
10
Dec
2020
Pfizer, BioNTech Vaccine Gets FDA Advisory OK. Now Comes More Hard Work
The good news this week was really one of those good news / bad news stories. An expert panel of FDA vaccine advisors looked at Pfizer’s presentation for the mRNA COVID-19 vaccine candidate, and saw the outstanding results for what they were. The vote was 17-4 (with one abstention) to recommend that the FDA give the go-ahead for an Emergency... Read More
8
Dec
2020
VC Roundup: Microglia Targeting, RNA Processing, and Radiopharmaceutical Startups Raise Cash
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Dec
2020
AZ’s Muddy Result, Regeneron Cocktail OK’d, and Biogen, Sage Bet Big on Depression
Take two weeks between Frontpoints columns, and a lot of stuff happens. On Monday Nov. 23, AstraZeneca presented a muddy picture from its Phase III clinical trial with a COVID-19 vaccine developed on adenovirus technology with Oxford University. It’s either delivering 90 percent efficacy or 62 percent efficacy, depending on the dose. So it’s either great or good, but we’re... Read More
2
Dec
2020
Genesis Therapeutics, AI Drug Discovery Startup, Captures $52M Series A
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Nov
2020
5AM, Atlas Join $40M Bet on Kinaset, a Pan-JAK Inhibitor for Severe Asthma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Nov
2020
Medicines Based on Unusual Genetic Traits: Andrew Farnum on The Long Run
Today’s guest on The Long Run is Andrew Farnum. Andrew is the CEO of Seattle-based Variant Bio. Variant Bio is a startup seeking to discover new drugs, by finding gene variants in rare ethnic groups. It’s especially interested in what can be learned by sequencing exceptional groups of people in countries where there hasn’t been much sequencing. This is a... Read More
20
Nov
2020
Moderna, Pfizer Nail COVID-19 Vaccines. Now Comes the Hard Part
It wasn’t the dominant headline it should have been, and few are in the mood to celebrate with the pandemic out of control, but this was a week to celebrate a monumental scientific victory that provides hope for 2021. Moderna dazzled everyone on Monday by reporting its mRNA vaccine candidate for COVID-19, developed in partnership with the National Institute for... Read More
12
Nov
2020
Pfizer, BioNTech’s Watershed Moment, Lilly Antibody Gets EUA, & The Rebuilding Begins
First thing Monday, we all woke up to the brightest ray of light in this dark year. Pfizer and Germany-based BioNTech reported that their vaccine candidate was found to be more than 90 percent effective at preventing COVID-19. The report was via press release, not peer-reviewed journal, but this was still a moment to celebrate. The interim analysis wasn’t based... Read More
11
Nov
2020
Creating the Future of Microbiome-Based Therapies: Simba Gill on The Long Run
Today’s guest on The Long Run is Simba Gill. Simba is the CEO of Cambridge, Mass.-based Evelo Biosciences. Evelo is part of a new generation of biotech companies seeking to make medicines based on new understanding of the microbiome. The science here is fascinating. Evelo’s drug candidates are biologics designed to be taken orally, to act directly in the gut,... Read More
5
Nov
2020
Reflections from a Wisconsin Boy
My first real journalism job flashed to mind this week. It was 1998-1999. I was a kid reporter fresh out of the University of Wisconsin. My job was to cover Dane County government for The Capital Times, the progressive newspaper in Madison. Dane County had about 400,000 people. Half lived in the beating liberal heart of the City of Madison... Read More
29
Oct
2020
J&J, AZ Back in the Saddle, Regeneron Moves the Ball Downfield, and a Flurry of Deals
America, my old conservative friend from a Mountain West state told me on the phone in April, can’t handle the pandemic. We’re soft, he said. Like the characters in the 2008 Pixar film “Wall-E,” he said, we’re sucking on our Slurpees and so drunk on cheap 24/7 entertainment that we can’t even stand on our own two feet anymore. ... Read More
28
Oct
2020
The Battle for the Soul of Biopharma: Peter Kolchinsky on The Long Run
Today’s guest on The Long Run is Peter Kolchinsky. Peter is the managing partner at RA Capital Management. The Boston-based firm invests in public and private life sciences companies with a total of $6.8 billion under management. Peter is a virologist by training at Harvard University. It’s obviously a valuable set of skills to have in a year like this.... Read More
26
Oct
2020
Machine Learning for Drug Discovery: Daphne Koller on The Long Run
Today’s guest on The Long Run is Daphne Koller. Daphne is the CEO of South San Francisco-based insitro. The company is seeking to develop a new platform for drug discovery that leans on a combination of wet labs and machine learning algorithms to spot new biological targets for drug discovery. Artificial intelligence and machine learning have been stirring imaginations in... Read More
22
Oct
2020
Remdesivir’s FDA Approval, Moderna Fully Enrolls & FDA Wrestles With Trust
Catch up on the main events of the week in biotech with Frontpoints. The FDA issued a surprising approval – not another watered-down Emergency Use Authorization – to Gilead Sciences for remdesivir (Veklury) its antiviral against COVID-19. The antiviral, designed to stop the SARS-CoV-2 virus from copying itself, is now the first treatment fully approved by the FDA against this... Read More
15
Oct
2020
J&J Vaccine Study Paused, Lilly Antibody Paused, and Regeneron’s Ebola FDA Approval
It’s hard to tell yet whether the J&J vaccine and Eli Lilly antibody trials are suffering from momentary blips, or something more serious on the safety front. The AstraZeneca vaccine trial has been stuck on pause in the US since September, which seems like a rather lengthy delay in pandemic terms. Let’s hope they all get back in the saddle... Read More